Articles
8 June 2009
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
https://doi.org/10.4081/hmr.v2i7.438

New treatment strategies for elderly myeloma patients

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
162
Views
226
Downloads

Authors

A Palumbo
support@pagepress.org
P Falco
P Musto
G Rossi
N Giuliani
F Morabito
A Falcone
In the treatment of elderly patients, the new paradigm is the combination of the old drug melphalan with the new drugs thalidomide, lenalidomide or bortezomib. In newly diagnosed multiple myeloma (MM) patients, the combination melphalan, prednisone and thalidomide (MPT) induces a fast tumor response with a high response rate, but evidence that this translate into improved outcome is limited. This multicenter trial compared the efficacy and the toxicity of oral MPT with oral melphalan and prednisone (MP) in previously untreated patients.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



New treatment strategies for elderly myeloma patients. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.438